1. Sarin, S. K. et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 10, 1-98 (2016).
2. Ott, J. J., Stevens, G. A., Groeger, J. & Wiersma, S. T. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 30, 2212-2219 (2012).
3. Terrault, N. A. et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 63, 261-283 (2016).
4. Fontana, R. J. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology. 49, S185-195 (2009).
5. Ting-Tsung Chang, M. D., Robert G. Gish, M.D., Robert de Man, M.D., Adrian Gadano, M.D., José Sollano, M.D., You-Chen Chao, M.D., Anna S. Lok, M.D., Kwang-Hyub Han, M.D., Zachary Goodman, M.D., Ph.D., Jin Zhu, Ph.D., Anne Cross, Ph.D., Deborah DeHertogh, M.D., Richard Wilber, M.D., Richard Colonno, Ph.D., and David Apelian, M.D., Ph.D., for the BEHoLD AI463022 Study Group*. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. N Engl J Med, 354:1001-1010. (2006).
6. George K.K. Lau, M. D., Teerha Piratvisuth, M.D., Kang Xian Luo, M.D., Patrick Marcellin, M.D., Satawat Thongsawat, M.D., Graham Cooksley, M.D., Edward Gane, M.D., Michael W. Fried, M.D., Wan Cheng Chow, M.D., Seung Woon Paik, M.D., Wen Yu Chang, M.D., Thomas Berg, M.D., Robert Flisiak, M.D., Philip McCloud, Ph.D., and Nigel Pluck, M.D.,. Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. The New England Journal of Medicine, 352;326 (june 30, 2005).
7. Lok, A. S. & McMahon, B. J. Chronic hepatitis B. Hepatology. 45, 507-539 (2007).
8. Piratvisuth, T. et al. Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol Int. 2, 102-110 (2008).
9. Bonino, F. et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 56, 699-705 (2007).
10. Martinot-Peignoux, M., Lapalus, M., Asselah, T. & Marcellin, P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 34 Suppl 1, 97-107 (2014).
11. Bartel, D. P. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. Vol. 116, 281–297 (2004).
12. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell. 136, 215-233 (2009).
13. Brunetto, M. R. et al. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. PLoS One. 9, e110782 (2014).
14. Fujita, K. et al. Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients. Int J Mol Sci. 19 (2018).
15. Brunetto, M. R. et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 49, 1141-1150 (2009).
16. Vlachogiannakos, J. & Papatheodoridis, G. V. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa? Liver Int. 34 Suppl 1, 127-132 (2014).
17. Lampertico, P., Vigano, M. & Colombo, M. Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon? Liver Int. 33 Suppl 1, 157-163 (2013).
18. Chuaypen, N. et al. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy. Clin Microbiol Infect. 24, 306 e307-306 e313 (2018).
19. Baker, M. A. et al. MiR-192-5p in the Kidney Protects Against the Development of Hypertension. Hypertension. 73, 399-406 (2019).
20. Mao, Q. et al. Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-beta1/Smad/miR-192 signaling pathway. Exp Ther Med. 18, 3053-3061 (2019).
21. Zou, P. et al. miR-192-5p suppresses the progression of lung cancer bone metastasis by targeting TRIM44. Sci Rep. 9, 19619 (2019).
22. Tavakolian, S., Goudarzi, H. & Faghihloo, E. Evaluating the expression level of miR-9-5p and miR-192-5p in gastrointestinal cancer: introducing novel screening biomarkers for patients. BMC Res Notes. 13, 226 (2020).
23. Flammang, I., Reese, M., Yang, Z., Eble, J. A. & Dhayat, S. A. Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 12 (2020).
24. Gu, Y. et al. miR-192-5p Silencing by Genetic Aberrations Is a Key Event in Hepatocellular Carcinomas with Cancer Stem Cell Features. Cancer Res. 79, 941-953 (2019).
25. Ren, F. J., Yao, Y., Cai, X. Y. & Fang, G. Y. Emerging Role of MiR-192-5p in Human Diseases. Front Pharmacol. 12, 614068 (2021).
26. Argyropoulos, C. et al. Urinary MicroRNA Profiling Predicts the Development of Microalbuminuria in Patients with Type 1 Diabetes. J Clin Med. 4, 1498-1517 (2015).
27. Wen, Y. et al. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma. Int J Cancer. 137, 1679-1690 (2015).
28. Pirola, C. J. et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 64, 800-812 (2015).
29. Nielsen, K. O. et al. Hepatitis B virus upregulates host microRNAs that target apoptosis-regulatory genes in an in vitro cell model. Exp Cell Res. 371, 92-103 (2018).
30. van der Ree, M. H. et al. Plasma MicroRNA Levels Are Associated With Hepatitis B e Antigen Status and Treatment Response in Chronic Hepatitis B Patients. J Infect Dis. 215, 1421-1429 (2017).
31. Zhang, X., Daucher, M., Armistead, D., Russell, R. & Kottilil, S. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha. PLoS One. 8, e55733 (2013).
32. Motawi, T. K., Shaker, O. G., El-Maraghy, S. A. & Senousy, M. A. Serum interferon-related microRNAs as biomarkers to predict the response to interferon therapy in chronic hepatitis C genotype 4. PLoS One. 10, e0120794 (2015).
33. Shin, K. H., Lee, H. J., Chang, C. L. & Kim, H. H. Performance of the cobas Hepatitis B virus (HBV) test using the cobas 4800 system and comparison of HBV DNA quantification ability between the COBAS AmpliPrep/COBAS TaqMan HBV test version 2.0 and cobas HBV test. J Clin Virol. 101, 47-51 (2018).
34. Matsuura, K. et al. Circulating let-7 Levels in Serum Correlate With the Severity of Hepatic Fibrosis in Chronic Hepatitis C. Open Forum Infect Dis. 5, ofy268 (2018).